XGN Form 4: CEO sold 31,787 shares to cover RSU taxes

Rhea-AI Filing Summary

Exagen Inc. (XGN) disclosed an insider transaction by its President and CEO, who is also a Director. On 10/16/2025, he sold 31,787 shares of common stock at $11.8161 per share, coded “S.”

According to the footnote, the sale was a mandated “sell to cover” to satisfy tax withholding on the vesting and settlement of Restricted Stock Units, and it was not a discretionary transaction by the reporting person.

Following the transaction, the reporting person beneficially owned 714,427 shares directly, plus 40,401 shares indirectly held by spouse.

Insider Trade Summary

Net Seller: 31,787 shares ($375,598)

Net Sell 2 txns

Insider ABALLI JOHN

Role President and CEO

Sold 31,787 shs ($376K)

Type	Security	Shares	Price	Value
Sale	Common Stock	31,787	$11.8161	$376K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 714,427 shares (Direct); Common Stock — 40,401 shares (Indirect, by Spouse)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ABALLI JOHN

(Last) (First) (Middle)

C/O EXAGEN INC.

1261 LIBERTY WAY

(Street)

VISTA CA 92081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXAGEN INC. [ XGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/16/2025		S(1)		31,787	D	$11.8161	714,427	D
Common Stock								40,401	I	by Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Remarks:

	/s/ Jeffrey G. Black, as attorney-in-fact	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Exagen (XGN) report on Form 4?

The President and CEO (also a Director) sold 31,787 shares of common stock on 10/16/2025.

At what price were the XGN shares sold?

The shares were sold at an average price of $11.8161 per share.

Why did the Exagen CEO sell shares?

Per the footnote, it was a mandated “sell to cover” to satisfy tax withholding on RSU vesting and settlement, not a discretionary trade.

How many Exagen shares does the CEO own after the sale?

He beneficially owns 714,427 shares directly and 40,401 shares indirectly through his spouse.

What roles does the reporting person hold at Exagen (XGN)?

He is the company’s President and CEO and also a Director.

What transaction code was used in the filing?

The transaction was reported with code S (sale).